Stock HROW HARROW, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets
Other stock markets
 04:00:00 2024-05-16 pm EDT 		5-day change 1st Jan Change
16.16 USD +1.48% Intraday chart for Harrow, Inc. +57.05% +44.29%
May. 15 B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating MT
May. 14 Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024

Evolution of the average Target Price on Harrow, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d2ae8c6335896e0a92eb.s_nHYhtUBC33JU9bXwwMwstgJWtjzfdw21VtNk9Ay2k.gdSRIGEkMGi9ZiwhcnU9kPoUZFNSgcc57mEERwMZgRrHsvMFV21VaoUQBg~27e97f4d36f13b7993496b8c68ac7f6c

Analyst Recommendations on Harrow, Inc.

B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating MT
Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating MT
B. Riley Lowers Harrow's PT to $30 From $45 After Lower-Than-Expected Q3 Results, Reduced Q4 Guidance; Keeps Buy Rating MT
B. Riley Raises Harrow Health's PT to $45 From $42 on Heels of Announced Transactions With Santen, Novaliq; Keeps Buy Rating MT
B. Riley Raises Harrow Health's Price Target to $42 From $24, Keeps Buy Rating MT
Lake Street Adjusts Price Target on Harrow Health to $37 From $24, Maintains Buy Rating MT
B. Riley Lifts Harrow Health's PT to $24 From $22 Accounting for Additional Incremental Revenues From Fab-Five Products, Ramp Up of IHEEZO Sales Trajectory in 2024; Keeps Buy Rating MT
B. Riley Raises Harrow Health's PT to $22 From $17 on Heels of Acquisition of 5 New Ophthalmology Products, Keeps Buy Rating MT
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and 'BB' Rating from Egan-Jones AQ
B. Riley Securities Resumes Harrow Health at Buy with $17 Price Target, Says Well-Positioned to Maintain Robust Momentum MT
B. Riley Raises Harrow Health's Price Target to $20 from $17 After Higher-than-Expected Q1 Revenue, Keeps Buy Rating MT
HARROW HEALTH : B. Riley Resumes Harrow Health at Buy with $16 PT, Says Well-Positioned to Maintain Momentum with Recent Q2 Beat, M&A Execution MT
HARROW HEALTH : Aegis Capital Starts Harrow Health at Buy with $15 Price Target MT
Harrow Health : Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones (Form 8-K) PU
HARROW HEALTH : B. Riley Adjusts Harrow Health's Price Target to $14 From $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.16 USD
Average target price
26.15 USD
Spread / Average Target
+61.82%
High Price Target
32.6 USD
Spread / Highest target
+101.73%
Low Price Target
20 USD
Spread / Lowest Target
+23.76%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Harrow, Inc.

B. Riley
Craig-Hallum
Lake Street
Aegis Capital

Ratings for Harrow, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HROW Stock
  4. Consensus Harrow, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW